Related Experiment Video
Updated: Mar 21, 2026

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis
Published on: July 18, 2017
Acute Kidney Injury in a Child Receiving Vancomycin and Piperacillin/Tazobactam
Bethany W Ibach1, Emilie D Henry2, Peter N Johnson3
1Texas Tech University Health Sciences Center School of Pharmacy, Abilene, Texas.
Insights
This case report highlights a child who developed acute kidney injury (AKI) when treated with vancomycin and piperacillin/tazobactam. Renal function improved after discontinuing the antibiotics, suggesting a drug-related adverse event.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
- Infectious Diseases
Background:
- Concomitant use of vancomycin and piperacillin/tazobactam is increasingly reported to cause acute kidney injury (AKI) in adults.
- Limited data exists regarding the risk of AKI associated with this antibiotic combination in pediatric populations.
Observation:
- An 8-year-old girl in the pediatric intensive care unit developed AKI during treatment for pneumonia with vancomycin and piperacillin/tazobactam.
- Discontinuation of both antibiotics led to the resolution of AKI, with serum creatinine returning to baseline.
- The patient later tolerated piperacillin/tazobactam monotherapy without evidence of renal impairment.
Findings:
- The Naranjo probability scale indicated a probable drug-related adverse event.
- This case suggests a potential link between vancomycin and piperacillin/tazobactam combination therapy and AKI in children.
Implications:
- Clinicians should maintain a high index of suspicion for AKI when prescribing this antibiotic combination to pediatric patients.
- Vigilant monitoring of renal function and vancomycin drug levels is crucial.
- Further prospective studies are warranted to determine the incidence and characteristics of AKI in children receiving vancomycin and piperacillin/tazobactam.
Abstract:
Recent reports have described increased risk of acute kidney injury (AKI) in adults receiving concomitant vancomycin and piperacillin/tazobactam, but few reports exist in children. We describe an 8-year-old girl who was admitted to the pediatric intensive care unit with respiratory distress secondary to pneumonia. She began treatment with vancomycin and piperacillin/tazobactam. She developed AKI, and piperacillin/tazobactam and vancomycin were discontinued. Following a furosemide infusion, her AKI resolved and serum creatinine returned to baseline. She later resumed piperacillin/tazobactam monotherapy for multidrug-resistant tracheitis with no evidence of AKI and was eventually discharged to a long-term care facility. The Naranjo probability scale supports a probable drug-related adverse event. Clinicians must be aware of the possibility of AKI with this combination and should monitor renal function and vancomycin concentrations vigilantly. Future prospective studies are needed to explore the incidence and clinical characteristics associated with AKI after this combination in children.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management

